Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | F13A1 | P00488 | 3/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337031 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL336648 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL1230060 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL25406852 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL25408775 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL25408793 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL25408300 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL25407766 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL905403 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 | |
| SCHEMBL337556 | 1.00 | TSHR (0.43) | TSHRLMNANFKB1PMP22PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE36359-E | SUCH AS N-(15-CARBOXYPENTADECANOYLOXY)SUCCINIMIDE; USED TO MODIFY PROTEINS TO OBTAIN PROTEIN DERIVATIVES HAVING IMPROVED BIOAVAILABILITY, NO ANTIGENICITY AND CAN BE ADMINISTERED TO ANIMALS | KURARAY CO., LTD. (JP) | 1999-10-26 | — | — | US | claimed |
| US-5336782-A | N-(carboxyalkoyloxy)succinimides; modifiers of proteins and enzymes to prolong their plasma half-lives; nontoxic; antitumor and -carcinogenic agents | KURARAY CO., LTD. (JP) | 1994-08-09 | — | — | US | claimed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2024-01-25 | — | — | US | disclosed |
| WO-2023245061-A2 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS TO CNS TISSUE | Arrowhead Pharmaceuticals, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| WO-2023175536-A1 | LIPID MONOMERS FOR THERAPEUTIC DELIVERY OF RNA | JANSSEN BIOTECH, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| EP-4213883-A1 | OLIGONUCLEOTIDES CONJUGATED TO FATTY ACIDS | Astrazeneca AB (SE) | 2023-07-26 | — | — | EP | disclosed |
| EP-0944648-A1 | GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 1999-09-29 | — | — | EP | disclosed |
| WO-1999043706-A1 | DERIVATIVES OF GLP-1 ANALOGS | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043341-A1 | GLP-1 DERIVATIVES WITH HELIX-CONTENT EXCEEDING 25 %, FORMING PARTIALLY STRUCTURED MICELLAR-LIKE AGGREGATES | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043708-A1 | GLP-1 DERIVATIVES OF GLP-1 AND EXENDIN WITH PROTRACTED PROFILE OF ACTION | NOVO NORDISK A/S (DK) | 1999-09-02 | — | — | WO | disclosed |
| EP-0511600-B1 | Long chain carboxylic acid imide ester | KURARAY CO (JP) | 1999-03-17 | — | — | EP | disclosed |
| WO-1998008871-A1 | GLP-1 DERIVATIVES | NOVO NORDISK A/S (DK) | 1998-03-05 | — | — | WO | disclosed |
| US-5414089-A | Useful for modifying enzymes or proteins | KURARAY CO., LTD. (JP) | 1995-05-09 | — | — | US | disclosed |
| US-5336782-A | N-(carboxyalkoyloxy)succinimides; modifiers of proteins and enzymes to prolong their plasma half-lives; nontoxic; antitumor and -carcinogenic agents | KURARAY CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0511600-A2 | Long chain carboxylic acid imide ester | KURARAY CO., LTD. (JP) | 1992-11-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912997-B2 | RNAi agents for inhibiting expression of Superoxide Dismutase 1 (SOD1), compositions thereof, and methods of use | SOD1, SOD3, SMN1; SMN2 | TSHR 4636/4885LMNA 2101/4885NFKB1 2722/4885 |
| US-20240026363-A1 | RNAi Agents for Inhibiting Expression of Superoxide Dismutase 1 (SOD1), Compositions Thereof, and Methods of Use | SOD1, SOD3, SMN1; SMN2 | TSHR 4626/4885LMNA 2050/4885NFKB1 2712/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | TSHR 27/4885LMNA 4484/4885NFKB1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.